Outcomes of Reinduction With Nadofaragene Firadenovec [0.03%]
Nadofaragene Firadenovec 再诱导的疗效和安全性：一项 2 期研究结果
Bogdana Schmidt,Joshua J Horns,Mark D Tyson et al.
Bogdana Schmidt et al.
Incidence of local treatment and metastasis during active surveillance for patients with a small renal mass in a national multicenter prospective cohort [0.03%]
小型肾病活性监测患者局部治疗和转移的发病率——全国多中心前瞻性队列研究
Luke T Lavallée,Antonio Finelli,Simon Tanguay et al.
Luke T Lavallée et al.
Purpose: The objective of this study was to determine the incidence of local treatment and incidence of metastasis for patients with a solitary small renal mass (SRM) (≤4cm) initiating active surveillance (AS). ...
The Voided Volume Transit Point (VVtrans): A Novel Functional Biomarker for Staging Bladder Outlet Obstruction? [0.03%]
空腔容积过渡点（VVtrans）：一种用于分期膀胱出口梗阻的功能生物标志物吗？
Yu-Hsiang Lin,Kuo-Jen Lin,Chun-Te Wu
Yu-Hsiang Lin
Letter: Updates to Microhematuria: AUA/SUFU Guideline (2025) [0.03%]
关于微血尿的AUA/SUFU指南更新（2025年）(letter)
Shahrokh F Shariat,Bas W G van Rhijn,Christian Bolenz et al.
Shahrokh F Shariat et al.
Letter: A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study [0.03%]
信件：PRIME研究的随机三期试验：二甲双胍作为开始雄激素剥夺治疗患者的代谢综合征预防和干预措施试验
Yu-Hsiang Lin,Jau-Yuan Chen,Chun-Te Wu
Yu-Hsiang Lin
Uro-Science [0.03%]
泌尿科学杂志
Anthony Atala
Anthony Atala
Laser Efficacy for Stress Urinary Incontinence in Women: How Interpretation of the Evidence Matters [0.03%]
解读证据的重要性决定激光治疗女性压力性尿失禁的效果
Anne M Suskind
Anne M Suskind
Editorial Comment [0.03%]
编者按
Emily Huang,Matthew Mossanen
Emily Huang
Current Publication Priorities in Reconstructive Urology: What to Expect in The Journal of Urology® [0.03%]
泌尿外科重建的当前出版优先事项：《泌尿外科杂志》的重点内容预告
George E Koch,Maia VanDyke,Niels V Johnsen et al.
George E Koch et al.